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Abstract
During HIV infection of macrophages, the lysosomal protein cathepsin B is released and in-
duces neurotoxicity. Also, the levels of cathepsin B are increased in plasma and post-mortem
brain tissue of patients with HIV-associated dementia. Oxidative damage is increased in HIV- in-
fected patients, while antioxidants are decreased in HIV-associated dementia. Dimethyl fumarate
(DMF), an antioxidant, has been reported to decrease HIV replication and neurotoxicity caused by
HIV-infected macrophages. Since HIV also increases cathepsin B, we hypothesize that DMF will
also reduce cathepsin B release from HIV-infected macrophages. Monocyte-derived macrophages
(MDM) were isolated from healthy donors and inoculated with HIV-1ADA. After removal of in-
fection, MDM were treated with DMF at different concentrations (15, 30, and 60 µM) until day
12 post-infection, changing and collecting media every three days. HIV-1p24 and cathepsin B
levels were assessed from HIV-infected MDM supernatants at the end of cultures using ELISA.
Results indicate that DMF reduced HIV-1 replication and cathepsin B secretion from HIV-infected
macrophages, in a concentration-dependent manner, in comparison with vehicle (DMSO)-treated
controls. However, cathepsin B secretion was not affected by HIV infection in vehicle-treated
controls. In conclusion, DMSO may have had an unexpected effect in cathepsin B secretion in our
experiments, and this could explain why cathepsin B secretion was not affected by HIV infection.
Future experiments will include an untreated control group to determine if DMSO vehicle is hav-
ing an effect in cathepsin B secretion. This will lead us to determine the role of DMF in cathepsin
B secretion from HIV-infected macrophages.
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ABSTRACT   
During HIV infection of macrophages, the lysosomal protein cathepsin B is released and 
induces neurotoxicity. Also, the levels of cathepsin B are increased in plasma and post-mortem 
brain tissue of patients with HIV-associated dementia. Oxidative damage is increased in HIV- 
infected patients, while antioxidants are decreased in HIV-associated dementia. Dimethyl fumarate 
(DMF), an antioxidant, has been reported to decrease HIV replication and neurotoxicity caused by 
HIV-infected macrophages. Since HIV also increases cathepsin B, we hypothesize that DMF will 
also reduce cathepsin B release from HIV-infected macrophages. Monocyte-derived macrophages 
(MDM) were isolated from healthy donors and inoculated with HIV-1ADA. After removal of 
infection, MDM were treated with DMF at different concentrations (15, 30, and 60 µM) until day 
12 post-infection, changing and collecting media every three days. HIV-1 p24 and cathepsin B 
levels were assessed from HIV-infected MDM supernatants at the end of cultures using ELISA. 
Results indicate that DMF reduced HIV-1 replication and cathepsin B secretion from HIV-infected 
macrophages, in a concentration-dependent manner, in comparison with vehicle (DMSO)-treated 
controls. However, cathepsin B secretion was not affected by HIV infection in vehicle-treated 
controls. In conclusion, DMSO may have had an unexpected effect in cathepsin B secretion in our 
experiments, and this could explain why cathepsin B secretion was not affected by HIV infection. 
Future experiments will include an untreated control group to determine if DMSO vehicle is 
having an effect in cathepsin B secretion. This will lead us to determine the role of DMF in 
cathepsin B secretion from HIV-infected macrophages. 
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